Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease

[1]  R. Bateman,et al.  Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study , 2022, Alzheimer's research & therapy.

[2]  D. Berry,et al.  Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease , 2022, Alzheimer's research & therapy.

[3]  R. Bateman,et al.  Lecanemab in Early Alzheimer's Disease. , 2022, The New England journal of medicine.

[4]  D. Selkoe,et al.  Abundant Aβ fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer’s disease brains , 2022, bioRxiv.

[5]  L. Lannfelt,et al.  Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease , 2022, Neurotherapeutics.

[6]  Silvio R. Meier,et al.  A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice , 2022, Neurotherapeutics.

[7]  E. Masliah,et al.  Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody , 2022, Pharmaceutics.

[8]  Silvio R. Meier,et al.  In vivo imaging of alpha-synuclein with antibody-based PET , 2022, Neuropharmacology.

[9]  Silvio R. Meier,et al.  11C-PiB and 124I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention , 2021, The Journal of Nuclear Medicine.

[10]  X. Fang,et al.  Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size , 2021, Fluids and barriers of the CNS.

[11]  F. Edwards,et al.  Following spatial Aβ aggregation dynamics in evolving Alzheimer’s disease pathology by imaging stable isotope labeling kinetics , 2021, Science Advances.

[12]  P. Colavita,et al.  Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies , 2021, RSC chemical biology.

[13]  D. Holtzman,et al.  Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy , 2021, Nature.

[14]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[15]  Silvio R. Meier,et al.  Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer’s Disease , 2021, Molecular Imaging and Biology.

[16]  P. Weinreb,et al.  Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life , 2020, Nature Neuroscience.

[17]  D. Berry,et al.  A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody , 2020, Alzheimer's Research & Therapy.

[18]  D. Sehlin,et al.  SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease , 2020, Translational neurodegeneration.

[19]  Y. Wine,et al.  The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies , 2020, Frontiers in Immunology.

[20]  U. Jappe,et al.  Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events , 2020, Allergo Journal International.

[21]  T. Andresen,et al.  Targeting the transferrin receptor for brain drug delivery , 2019, Progress in Neurobiology.

[22]  Özgür A. Onur,et al.  Engineered antibodies: new possibilities for brain PET? , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Xiaotian T. Fang,et al.  High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain , 2019, NeuroImage.

[24]  Silvio R. Meier,et al.  Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition , 2018, The Journal of Nuclear Medicine.

[25]  L. Lannfelt,et al.  Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody , 2018, Alzheimer's Research & Therapy.

[26]  L. Lannfelt,et al.  The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death , 2018, Journal of Neuroinflammation.

[27]  T. Singer,et al.  Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode. , 2018, Cell reports.

[28]  L. Lannfelt,et al.  Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells , 2017, Biological Procedures Online.

[29]  L. Lannfelt,et al.  Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor , 2017, Theranostics.

[30]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[31]  L. Lannfelt,et al.  The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. , 2014, Journal of Alzheimer's disease : JAD.

[32]  T. Saido,et al.  New mouse model of Alzheimer's. , 2014, ACS chemical neuroscience.

[33]  S. Itohara,et al.  Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.

[34]  Anirvan Ghosh,et al.  Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.

[35]  W. Pardridge,et al.  Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. , 2013, Molecular pharmaceutics.

[36]  R. Sperling,et al.  New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF , 2013, Alzheimer's & Dementia.

[37]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[38]  F. Nikolajeff,et al.  Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation , 2012, PloS one.

[39]  W. Luk,et al.  Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.

[40]  Dag Sehlin,et al.  Heavy-Chain Complementarity-Determining Regions Determine Conformation Selectivity of Anti-Aβ Antibodies , 2010, Neurodegenerative Diseases.

[41]  L. Lannfelt,et al.  An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease , 2009, Neurobiology of Disease.

[42]  Morten Nielsen,et al.  NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction , 2009, BMC Bioinformatics.

[43]  B. Engelhardt,et al.  Immunohistochemical localization of the murine transferrin receptor (TfR) on blood–tissue barriers using a novel anti-TfR monoclonal antibody , 1998, Histochemistry and Cell Biology.

[44]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.

[45]  T. Golde.  Alzheimer's Research & Therapy , 2009 .

[46]  L. Lannfelt,et al.  Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. , 2007, Journal of neurochemistry.

[47]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..